Crossmark

Imatinib and CAR T cell therapy enable sustained response in a young patient with refractory RCSD1-ABL1-positive acute lymphoblastic leukemia

Published Online: 2023-10-21

Published Print: 2024-01

Authors

Cui, Yajuan

Peng, Hongling https://orcid.org/0000-0003-2770-5150
License Information

Text and Data Mining valid from 2023-10-21

Version of Record valid from 2023-10-21
More Information

Article History

Received: 10 September 2023

Accepted: 28 September 2023

First Online: 21 October 2023

Declarations

:

: A written informed consent was obtained from the patient for the publication.

: The authors declare no competing interests.

Document is current